We are live on ! Find out more
NFGH

Nan Fung Group Holdings Portfolio holdings

AUM $121M
1-Year Est. Return 56.89%
This Fund
S&P 500
This Quarter Est. Return
-3.86%
1 Year Est. Return
+56.89%
3 Year Est. Return
+244.35%
5 Year Est. Return
+210.19%
10 Year Est. Return
–
AUM
$312M
AUM Growth
-$9.44M
Cap. Flow
+$91.4M
Cap. Flow %
29.26%
Top 10 Hldgs %
89.79%
Holding
29
New
5
Increased
4
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$61.3M
2
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
+$19.1M
3
RANI icon
Rani Therapeutics
RANI
+$8.54M
4
VIR icon
Vir Biotechnology
VIR
+$3.96M
5
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$757K

Top Sells

Rank Stock Value
1
ARDX icon
Ardelyx
ARDX
+$2.46M
2
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$1.56M

Sector Composition

Rank Sector Weight
1 Healthcare 67.1%
2 Financials 30.02%
3 Communication Services 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NFH
1
DELISTED
New Frontier Health Corporation Ordinary Shares
NFH
$93.8M 30.02%
8,350,000
– –
ILMN icon
2
Illumina
ILMN
$31B
$52.6M 16.83%
+133,277
New +$61.3M
HRMY icon
3
Harmony Biosciences
HRMY
$2.08B
$29.5M 9.43%
768,708
– –
KRTX
4
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$28.7M 9.19%
234,811
– –
SLGC
5
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$21M 6.73%
+1,696,558
New +$19.1M
EAR
6
DELISTED
Eargo, Inc. Common Stock
EAR
$19.4M 6.22%
144,336
– –
BOLT icon
7
Bolt Biotherapeutics
BOLT
$7.47M
$14.8M 4.73%
58,348
– –
RANI icon
8
Rani Therapeutics
RANI
$92.2M
$8.8M 2.82%
+493,584
New +$8.54M
VIR icon
9
Vir Biotechnology
VIR
$1.5B
$6.97M 2.23%
160,211
+91,548
+133% +$3.96M
GRTX
10
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$4.97M 1.59%
613,223
– –
BEAM icon
11
Beam Therapeutics
BEAM
$2.73B
$4.78M 1.53%
54,903
+6,243
+13% +$627K
NFH.WS
12
DELISTED
New Frontier Health Corporation Warrants, each whole warrant exercisable for one Ordinary Share at a
NFH.WS
$4.46M 1.43%
1,580,000
– –
NVTA
13
DELISTED
Invitae Corporation
NVTA
$4.11M 1.32%
144,667
– –
ALXO icon
14
ALX Oncology
ALXO
$262M
$3.1M 0.99%
41,950
+7,000
+20% +$467K
XENE icon
15
Xenon Pharmaceuticals
XENE
$6.2B
$3.02M 0.97%
197,880
– –
DBVT
16
DBV Technologies
DBVT
$817M
$1.82M 0.58%
37,095
+8,545
+30% +$441K
EXAS
17
DELISTED
Exact Sciences
EXAS
$1.67M 0.53%
17,464
– –
OTIC
18
DELISTED
Otonomy, Inc.
OTIC
$1.63M 0.52%
851,000
– –
KALV
19
DELISTED
KalVista Pharmaceuticals
KALV
$1.37M 0.44%
78,720
– –
EXEL icon
20
Exelixis
EXEL
$14.1B
$1.36M 0.43%
64,200
– –
SRRA
21
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$1.16M 0.37%
52,979
-78,000
-60% -$1.56M
RUBY
22
DELISTED
Rubius Therapeutics, Inc
RUBY
$1.01M 0.32%
56,768
– –
RETA
23
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$832K 0.27%
8,265
– –
STSA
24
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$666K 0.21%
+142,900
New +$757K
FLNT
25
Fluent
FLNT
$104M
$442K 0.14%
32,467
– –
1
2

Similar funds

TCM
TT Capital Management Coto De Caza, California $121M AUM 1.94% 1-Year Est. Return
MAM
Mirabaud Asset Management London, United Kingdom $121M AUM 20.69% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
CCM
Candelo Capital Management New York $121M AUM 113.39% 1-Year Est. Return
CCM
CFO Capital Management Fairfield, Connecticut $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Nan Fung Group Holdings's Q3 2021 Portfolio in Review

As of Q3 2021, Nan Fung Group Holdings held 29 positions worth $312M, down 2.9% from $322M the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Nan Fung Group Holdings deployed $91.4M of net new capital in Q3 2021, opening 5 new positions and adding to 4 existing holdings. Its largest new stake was Illumina: 133,277 shares worth $52.6M.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, down from 68% a quarter earlier, followed by Financials and Communication Services.

On the sell side, the largest reduction was Sierra Oncology, Inc. Common Stock, an estimated $1.56M trimmed.

  • Nan Fung Group Holdings's largest Q3 2021 buy was Illumina: 133,277 shares worth $52.6M.
  • Nan Fung Group Holdings added most to Vir Biotechnology in Q3 2021, an estimated $3.96M increase.
  • Nan Fung Group Holdings's biggest Q3 2021 reduction was Sierra Oncology, Inc. Common Stock, cutting an estimated $1.56M.
  • Nan Fung Group Holdings fully exited Ardelyx in Q3 2021, selling an estimated $2.46M.
  • Nan Fung Group Holdings's ten largest holdings make up 90% of its $312M portfolio in Q3 2021.
  • Nan Fung Group Holdings opened 5 new positions and closed 1 in Q3 2021.
  • Nan Fung Group Holdings's portfolio value fell 2.9% quarter-over-quarter to $312M.

Based on Nan Fung Group Holdings's 13F filing for Q3 2021, filed 15 Nov 2021.